Navigation Links
FDA Approves ALOXI(R) (Palonosetron HCl) Capsules for Prevention of Acute Chemotherapy-induced Nausea and Vomiting
Date:8/23/2008

stribution and marketing rights for ALOXI from Helsinn Healthcare SA.

About HELSINN HEALTHCARE SA

HELSINN HEALTHCARE SA is a privately owned pharmaceutical group with headquarters in Switzerland and is the worldwide licensor of palonosetron. HELSINN's core business is the licensing of pharmaceuticals in therapeutic niche areas. The company's business strategy is to in-license early stage new chemical entities and complete their development from the performance of pre-clinical/clinical studies and CMC development to the attainment of market approvals in strategic markets (U.S. and Europe). HELSINN's products are eventually out-licensed to its marketing partners for distribution. The active pharmaceutical ingredients and the finished dosage forms are manufactured at HELSINN's cGMP facilities and supplied worldwide to its customers. For more information about HELSINN, please visit the company's Web site at http://www.helsinn.com.

About Eisai Corporation of North America

Eisai Corporation of North America is a wholly-owned subsidiary of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: neurology, gastrointestinal disorders and oncology/critical care.

Eisai Corporation of North America supports the activities of its operating companies in North America, which include: Eisai Research Institute of Boston, Inc., a discovery operation with strong organic chemistry capabilities; Morphotek, Inc., a biopharmaceutical company specializing in the development of therapeutic monoclonal antibodies; Eisai Medical Research Inc., a clinical development group; Eisai Inc., a commercial operation with manufacturing and marketing/sales functions; and Eisai Machinery U.S.A., which markets and maintains pharmaceutical manufacturing machinery.


'/>"/>
SOURCE Eisai Corporation of North America
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. USDA Approves Syngenta and John Deere for Broadened Biotechnology Endorsement for Corn Crop Insurance
2. Signalife Board Approves Merger
3. FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions
4. FDA Approves Abbotts XIENCE(TM) V Drug Eluting Stent
5. FDA Approves ACIPHEX(R) (rabeprazole sodium) 20 mg for Short-Term Treatment of GERD in Adolescents
6. FDA Approves CONCERTA(R) (methylphenidate HCI) Extended-release Tablets for Treatment of ADHD (Attention Deficit Hyperactivity Disorder) in Adults
7. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
8. Big Win for Biodiesel: ASTM Approves New Biodiesel Blend Specifications
9. FDA Approves GlaxoSmithKlines AVODART(R) in Combination with Tamsulosin for the Treatment of Symptomatic Enlarged Prostate
10. Arpida Annual General Meeting of Shareholders Approves All Board Proposals
11. FDA Approves MIXJECT(TM), a Convenient, Easy-to-Use Drug Delivery System For Watson Pharmaceuticals TRELSTAR(R) DEPOT and TRELSTAR(R) LA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... Calif. , March 4, 2015 ... a specialty pharmaceutical company focused on the development ... of acute and breakthrough pain, today announced that ... financial results after market close on Monday, March ... conference call at 4:30 p.m. Eastern Time (1:30 ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 Follow ... represents one of the fastest growing technologies in the ... in subcellular visualization is driving growth in nucleic acid ... deeper understanding of gene expressions will continue to benefit ... applications in fields ranging from pharma, biotech, food & ...
(Date:3/4/2015)... , March 4, 2015 ... Entwicklungen für Diagnostik und Therapie, Strahlendosismanagement und IT-Lösungen ... Royal Philips (NYSE: PHG, AEX: ... Röntgenkongress 2015 (ECR) bekannt, der vom 4. bis ... An den Ständen Nr. 102 and 110 ...
(Date:3/3/2015)... 2015 NASA astronaut Scott Kelly , who ... spend a year living and working on the International Space ... to 7 a.m. EDT Monday, March 9. Kelly ... completes the final weeks of his training. The interviews will ... Television highlighting his mission training and previous spaceflights. ...
Breaking Biology Technology:AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 2AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 2Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 4Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 2Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 3Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 4Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 5Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 6NASA Astronaut Scott Kelly Available for Interviews before One-Year Space Station Mission 2
... Present Company Overview-, PRINCETON, N.J. and SAN ... focused on the development of medicines with,novel mechanisms ... present a corporate overview at the 2008 BIO ... will summarize the,current status of the company including ...
... FREMONT, Calif., Oct. 23 WaferGen Biosystems,Inc. (OTC ... expression, genotyping, cell biology and stem cell research ... chief,executive officer, will deliver a corporate presentation at ... be held October 28-31, 2008,at the Palace Hotel ...
... Conference Call to be Held on November 13, 2008 ... / 5:00 am (Pacific) / 9:00 pm (Beijing/Hong Kong), ... Inc. (NYSE: WX ), a leading pharmaceutical, biotechnology ... and the,United States, today announced that it will release ...
Cached Biology Technology:Tobira Therapeutics, Inc. to Present at the 2008 BIO Investor Forum 2WaferGen to Present at the Seventh Annual BIO Investor Forum 2WuXi PharmaTech Schedules Third Quarter 2008 Earnings Release on Wednesday, November 12, 2008 2
(Date:2/10/2015)...  Alere Inc. (NYSE: ALR), a global leader ... the quarter ended December 31, 2014. ... Alere said, "We made substantial progress in the ... leader in rapid diagnostics and delivering against our ... in early January enabled us to substantially reduce ...
(Date:2/5/2015)... TRIANGLE PARK, North Carolina , 5. ... sein 35. Jahr als spezialisiertes Logistikunternehmen und ... Position als einzige klinische Logistikfirma (Clinical Logistics ... Die Kernbotschaft der neuen Kampagne lautet ... und Lieferungen. Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
(Date:2/5/2015)... , Jan. 26, 2015   Epic Sciences , ... cancer, today announced that Murali Prahalad , Ph.D., president ... Medicine World Conference (PMWC) 2015: Silicon Valley, which is ... Mountain View, Calif. on January 26-28, 2015. ... Come of Age as Biomarkers." Last year, Epic Sciences was ...
Breaking Biology News(10 mins):Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34Alere Inc. Announces Fourth Quarter 2014 Results 35Alere Inc. Announces Fourth Quarter 2014 Results 36
... Dec. 18, 2013 Tissue engineering is a ... or reparative medicine with potential to circumvent organ ... involve leveraging technologies from biomaterials, molecular medicine, biochemistry, ... and/or repair of human organs through regeneration and ...
... RICHLAND, Wash. Engineers have created a continuous chemical process ... harvested algae a verdant green paste with the ... the Department of Energy,s Pacific Northwest National Laboratory was reported ... company, Utah-based Genifuel Corp., has licensed the technology and is ...
... or Moderate Resolution Imaging Spectroradiometer instrument that flies aboard ... detected the heat from the Pfeiffer Fire near Big ... EST. The red outlined area represents the heat from ... has destroyed at least 15 homes and caused many ...
Cached Biology News:State-of-the-Art Tissue Engineering and Organ Regeneration Technologies Yield Healthcare Market Disruption 2State-of-the-Art Tissue Engineering and Organ Regeneration Technologies Yield Healthcare Market Disruption 3State-of-the-Art Tissue Engineering and Organ Regeneration Technologies Yield Healthcare Market Disruption 4Algae to crude oil: Million-year natural process takes minutes in the lab 2Algae to crude oil: Million-year natural process takes minutes in the lab 3
RECOMBINANT EQUINE TNF ALPHA Product Type: Recombinant Protein...
... 10X concentrated solutions. REact Buffer SetConsists of one ... buffers and one 250 microl vial of 10 ... vials of REact 1 Buffer four 1 ml ... vials of REact 3 Buffer and four 1 ...
Porcine TNF-alpha/TNFSF1A ELISpot Development Module...
5-bromo-4-chloro-3-indolyl b -D-galactopyranoside (X-Gal)...
Biology Products: